New hope for rare blood disorder: gentler transplant trial aims to rebuild Patients' immune systems
NCT ID NCT04784052
First seen Jan 30, 2026 · Last updated Apr 12, 2026 · Updated 7 times
Summary
This trial is testing a new approach to stem cell transplantation for people with Fanconi Anemia, a genetic disorder that causes bone marrow failure. Researchers aim to use a special antibody and a less toxic conditioning regimen to help patients' bodies accept donor stem cells with fewer severe side effects than standard chemotherapy. The goal is to rebuild healthy blood and immune systems in participants, who will be followed for two years after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.